CriticalSelective serotonin reuptake inhibitor (SSRI)×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
Selegiline irreversibly inhibits the enzyme monoamine oxidase (MAO) type B. At the recommended dose of 5–10 mg a day it acts selectively on MAO-B, and above 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After a single 10 mg dose of selegiline, platelet MAO-B activity returns to normal in about 2 weeks, as the body makes new enzyme (selegiline SmPC, AEMPS). MAO takes part in the breakdown of serotonin (selegiline label, US Food and Drug Administration, FDA). Paroxetine is a potent selective serotonin reuptake inhibitor, so the Spanish SmPCs of both drugs contraindicate the combination because of the risk of serotonin syndrome (paroxetine and selegiline SmPCs, AEMPS). Serotonin syndrome, including fatal cases, has been reported in people taking selegiline together with antidepressants, and the mechanism of these reactions is not fully understood (selegiline FDA label).
Symptoms
Selegiline combined with selective serotonin reuptake inhibitors (SSRIs), the class paroxetine belongs to, may cause confusion, hypomania, hallucinations and manic episodes, agitation, myoclonus, overactive reflexes, poor coordination, shivering, tremor, seizures, ataxia, sweating, diarrhoea, fever and high blood pressure, all of which can be part of serotonin syndrome (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Serotonin syndrome or neuroleptic malignant syndrome during paroxetine treatment, especially with other serotonergic drugs, can be life-threatening. It presents with hyperthermia, rigidity, myoclonus, autonomic instability with rapid swings in vital signs, and mental changes such as confusion, irritability and extreme agitation progressing to delirium and coma (paroxetine SmPC, AEMPS). Similar signs have been reported in some patients taking selegiline 10 mg a day with SSRIs, paroxetine included (selegiline capsules label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The Spanish paroxetine summary of product characteristics (SmPC) contraindicates paroxetine with monoamine oxidase (MAO) inhibitors as a class, with linezolid as the only exception. According to its own SmPC, selegiline is an MAO type B inhibitor (paroxetine and selegiline SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). In turn, the Spanish selegiline SmPC contraindicates selegiline with selective serotonin reuptake inhibitors (SSRIs), the class paroxetine belongs to (selegiline SmPC, AEMPS). The US paroxetine label contraindicates paroxetine with any MAO inhibitor and within 14 days of stopping one, and the US label for the selegiline patch for depression names paroxetine among the contraindicated drugs (paroxetine and selegiline labels, US Food and Drug Administration, FDA). Start paroxetine no earlier than 2 weeks after stopping selegiline, with caution and with gradual dose increases, because selegiline inhibits MAO irreversibly (paroxetine and selegiline SmPCs, AEMPS; the paroxetine and selegiline FDA labels give at least 14 days). When switching the other way, allow at least one week between the last dose of paroxetine and the first dose of selegiline (paroxetine SmPC, AEMPS). If a patient is nevertheless taking both drugs and signs of serotonin syndrome appear, stop paroxetine and selegiline at once and start supportive symptomatic treatment (paroxetine SmPC, AEMPS, and FDA label; selegiline patch FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Selegiline hydrochloride capsules (Apotex Corp.) – prescribing information (2026)– FDA label, Apotex Corp., DailyMed setid 1924db3d-6a16-4496-cfd0-6903be146925, version 9, 09/2026, CONTRAINDICATIONS (meperidine), WARNINGS (tricyclic antidepressants and SSRIs: "it seems prudent, in general, to avoid this combination"), PRECAUTIONS: Drug Interactions
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Zelapar (selegiline hydrochloride) prescribing information (2021)– FDA label, Bausch Health US, LLC, DailyMed setid 380d7717-2a79-42f3-a712-efe5e7696ba0, revised 06/2021, sections 4, 5.1 and 7.1
- FDA: Emsam (selegiline transdermal system) prescribing information (2020)– FDA label, Viatris Specialty LLC, DailyMed setid b891bd9f-fdb8-4862-89c5-ecdd700398a3, revised 05/2020, section 4
- AEMPS: Ficha técnica: Paroxetina (nº registro 59466), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59466 (Frosinor 20 mg, GlaxoSmithKline), revisión 12/2025, secciones 4.3, 4.4 y 4.5